Access cutting-edge renal impairment after cardiac surgery treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Ann Arbor location
Preparing your pre-screening questions…
Access renal impairment after cardiac surgery specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related renal impairment after cardiac surgery treatment provided free
Check if you qualify for this renal impairment after cardiac surgery clinical trial in Ann Arbor, MI
No-Cost Study Care
Local to Ann Arbor
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively. This in turn is associated with an increased risk of prolonged intensive care unit (ICU) length of stay, other comorbidities including surgical complications and 30-day mortality. Renal impairment is generally identified based on an increase in serum creatinine concentration and/or a certain magnitude decrease in estimated glomerular filtration rate (eGFR). The JuxtaFlow® Renal Assist Device (RAD) is designed to sustain or enhance glomerular filtration perioperatively for patients with renal insufficiency by applying a mild controlled negative pressure to the collecting system via the renal pelvis, thereby increasing effective filtration pressure and reducing tubular pressure. This mechanism is designed to support the kidneys' functions during times of renal stress that would be associated with intrarenal edema, volume overload, increased venous pressure, and inflammatory response. By supporting renal function, specifically during the acute stress of CPB, JuxtaFlow holds promise to protect nephron function, decrease renal hypoxia, and provide multifactorial kidney function support to maintain their ability to manage future stress.
Sponsor: 3ive Labs
Yes, this clinical trial (NCT07017933) has an active research site in Ann Arbor, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for renal impairment after cardiac surgery treatment options in Ann Arbor, MI, this clinical trial (NCT07017933) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced renal impairment after cardiac surgery specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all renal impairment after cardiac surgery clinical trials near you to find additional studies recruiting in your area.
See all atrial fibrillation clinical trials recruiting in Ann Arbor — not just this study.
Browse Atrial Fibrillation Trials in Ann Arbor →